Phase 2 Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis

To evaluate the safety and efficacy of topical recombinant human nerve growth factor (rhNGF) for treating moderate-to-severe neurotrophic keratitis (NK), a rare degenerative corneal disease resulting from impaired corneal innervation.

Source: Ophthalmology - April 10, 2018 Category: Opthalmology Authors: Stefano Bonini, Alessandro Lambiase, Paolo Rama, Francesco Sinigaglia, Marcello Allegretti, Wendy Chao, Flavio Mantelli, REPARO Study Group Source Type: research